Study guide
4.1 Physicochemical Properties of Drugs
PSI Equivalence Examination Third Country Qualification Recognition
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Overview & TCQR Framework
1.1 TCQR Pathway and PSI Equivalence Exam Structure 1.2 PSI Core Competency Framework and MPharm Standard 1.3 Irish Healthcare System & Pharmacy Environment
2 Chapter 2: Pharmaceutical Calculations
2.1 Paediatric & Adult Dose Calculations 2.2 Percentage Strengths, Ratio Strengths & PPM Conversions 2.3 Dilutions, Alligations & Reconstitution 2.4 Infusion Rates, Syringe Drivers & Opioid Equianalgesic Conversions
3 Chapter 3: Pharmacology & Applied Pharmacokinetics
3.1 Receptor Pharmacology & Autonomic Nervous System 3.2 Cardiovascular & Renal Pharmacology 3.3 Central Nervous System & Antimicrobial Pharmacology 3.4 Pharmacokinetics & Narrow Therapeutic Index Drugs
4 Chapter 4: Basic Science & Pharmaceutics
4.1 Physicochemical Properties of Drugs 4.2 Dosage Form Formulation & Excipients 4.3 Drug Stability, Degradation & Bioequivalence
5 Chapter 5: Pharmacy Practice & Dispensing Workflow
5.1 Prescription Validation & Dispensing Workflow 5.2 Patient Counselling & Medicines Safety 5.3 Responding to Symptoms & Minor Ailments 5.4 Primary Care Schemes & Community Services
6 Chapter 6: Irish Pharmacy Law & Professional Ethics
6.1 Pharmacy Act 2007 & PSI Governance 6.2 Medicinal Products Regulations 6.3 Controlled Drugs Legislation & Misuse of Drugs Regulations 6.4 Professional Ethics & Code of Conduct
7 Chapter 7: Clinical Therapeutics & Disease State Management
7.1 Respiratory & Endocrine Therapeutics 7.2 Cardiovascular & Gastrointestinal Therapeutics 7.3 Infections, Antimicrobial Stewardship & Public Health 7.4 Special Populations & Complex Care
8 Chapter 8: OSCE & Practical Clinical Communication Skills
8.1 OSCE Station Structure & Core Competencies 8.2 Structured Patient Consultations & Devices Counselling 8.3 Prescriber Interventions, Ethical Dilemmas & Professional Judgement
4.1 Physicochemical Properties of Drugs
Key Takeaways Explain This Topic AI
The Henderson-Hasselbalch equation defines the quantitative ratio of ionized to un-ionized drug species based on environmental pH and drug pKa.
Non-ionized drug molecules exhibit substantially higher lipid solubility and cross biological membranes via passive diffusion far more rapidly than charged ionized species.
The octanol-water partition coefficient (logP) quantifies lipophilicity; an optimal logP between 1 and 3 balances membrane permeability with aqueous solubility.
Passive diffusion across biological membranes follows Fick's First Law, where solute flux is directly proportional to concentration gradient, surface area, and partition coefficient.
Solubility enhancement techniques include salt formation, solid dispersions, cyclodextrin inclusion complexes, micronization, and self-emulsifying drug delivery systems.
Last updated: July 2026
4.1 Physicochemical Properties of Drugs
Core Concept: The absorption, distribution, metabolism, and excretion (ADME) of a therapeutic agent are fundamentally governed by its physicochemical properties. Key parameters including acid dissociation constant ( p K a p K_a p K a ), environmental p H p H p H , lipophilicity ( log P \log P lo g P ), and aqueous solubility dictate how a drug molecule interacts with biological membranes and formulation matrices.
Understanding these molecular characteristics allows pharmaceutical scientists to predict systemic absorption across mucosal barriers, optimize drug stability, and select appropriate formulation technologies for poorly soluble compounds.
1. Drug Ionization, pH, and pKa
Most active pharmaceutical ingredients (APIs) are weak organic acids or weak organic bases. Unlike strong acids or bases that completely dissociate in aqueous solution, weak electrolytes exist in a dynamic equilibrium between their un-ionized (uncharged, molecular) and ionized (charged, ionic) forms.
The acid dissociation constant ( K a K_a K a ), expressed logarithmically as p K a = − log 10 ( K a ) p K_a = -\log_{10}(K_a) p K a = − lo g 10 ( K a ) , is the specific p H p H p H at which a drug molecule exists in exact 50 : 50 50:50 50 : 50 equilibrium between its ionized and un-ionized states. The relative proportion of ionized to un-ionized species at any physiological p H p H p H is quantitatively expressed by the Henderson-Hasselbalch equation .
Mathematical Equations
For a weak acid ( H A ⇌ H + + A − HA \rightleftharpoons H^+ + A^- H A ⇌ H + + A − ):
p H = p K a + log 10 ( [ A − ] [ H A ] ) = p K a + log 10 ( [ Ionized ] [ Un-ionized ] ) p H = p K_a + \log_{10}\left( \frac{[A^-]}{[HA]} \right) = p K_a + \log_{10}\left( \frac{[\text{Ionized}]}{[\text{Un-ionized}]} \right) p H = p K a + lo g 10 ( [ H A ] [ A − ] ) = p K a + lo g 10 ( [ Un-ionized ] [ Ionized ] )
Rearranging to determine the percentage of ionized weak acid:
% Ionized (Weak Acid) = 100 1 + 10 ( p K a − p H ) \% \text{ Ionized (Weak Acid)} = \frac{100}{1 + 10^{(p K_a - p H)}} % Ionized (Weak Acid) = 1 + 1 0 ( p K a − p H ) 100
For a weak base ( B H + ⇌ H + + B BH^+ \rightleftharpoons H^+ + B B H + ⇌ H + + B ):
p H = p K a + log 10 ( [ B ] [ B H + ] ) = p K a + log 10 ( [ Un-ionized ] [ Ionized ] ) p H = p K_a + \log_{10}\left( \frac{[B]}{[BH^+]} \right) = p K_a + \log_{10}\left( \frac{[\text{Un-ionized}]}{[\text{Ionized}]} \right) p H = p K a + lo g 10 ( [ B H + ] [ B ] ) = p K a + lo g 10 ( [ Ionized ] [ Un-ionized ] )
Rearranging to determine the percentage of ionized weak base:
% Ionized (Weak Base) = 100 1 + 10 ( p H − p K a ) \% \text{ Ionized (Weak Base)} = \frac{100}{1 + 10^{(p H - p K_a)}} % Ionized (Weak Base) = 1 + 1 0 ( p H − p K a ) 100
Clinical and Pharmacokinetic Implications
When environmental p H < p K a p H < p K_a p H < p K a , acidic environment forces weak acids into their un-ionized form ( H A HA H A ), while weak bases become predominantly ionized ( B H + BH^+ B H + ).
When environmental p H > p K a p H > p K_a p H > p K a , alkaline environment forces weak acids into their ionized form ( A − A^- A − ), while weak bases become predominantly un-ionized ( B B B ).
Rule of Thumb: A p H p H p H shift of 1 1 1 unit away from p K a p K_a p K a changes the ratio of ionized to un-ionized drug by a factor of 10 10 10 ; a shift of 2 2 2 units changes the ratio by a factor of 100 100 100 .
2. Ionization State vs. Lipid Solubility & Passive Membrane Diffusion
Biological membranes consist of a hydrophobic phospholipid bilayer embedded with proteins. According to the pH-Partition Hypothesis , only un-ionized, non-polar drug molecules possess sufficient lipophilicity to partition into and passively diffuse across lipid membranes. [Gastric Lumen: pH 1.5] [Lipid Membrane] [Blood Plasma: pH 7.4]
- Weak Acid (HA) [Un-ionized] <---> Passive Diffusion <---> Weak Acid (HA) [Un-ionized]
- ^
- v v
- Ionized (A-) [Low Conc.] Ionized (A-) [High Conc.] (Trapped)
- Ion Trapping Mechanism
When a total concentration gradient exists across membranes with a p H p H p H differential (e.g., stomach p H ≈ 1.5 p H \approx 1.5 p H ≈ 1.5 vs. plasma p H ≈ 7.4 p H \approx 7.4 p H ≈ 7.4 ), un-ionized drug equilibrates rapidly across the membrane. However, once in the higher p H p H p H plasma, weak acids ( p K a ≈ 3.5 p K_a \approx 3.5 p K a ≈ 3.5 , e.g., aspirin) dissociate into ionized species ( A − A^- A − ). Because A − A^- A − cannot cross back across the lipid barrier, the drug accumulates in plasma—a phenomenon known as ion trapping .
Conversely, clinical toxicologists exploit ion trapping during drug overdose management. Alkalinizing the urine with intravenous sodium bicarbonate ( p H > 7.5 p H > 7.5 p H > 7.5 ) converts weak acids (such as phenobarbital or salicylates) into their ionized state within renal tubules, preventing tubular reabsorption and accelerating urinary excretion.
Fick's First Law of Diffusion
Passive membrane transport driven by a concentration gradient is quantitatively defined by Fick's First Law :
J = D ⋅ K ⋅ A ⋅ ( C 1 − C 2 ) h J = \frac{D \cdot K \cdot A \cdot (C_1 - C_2)}{h} J = h D ⋅ K ⋅ A ⋅ ( C 1 − C 2 )
- Variable Parameter Description Pharmacokinetic Influence
- J J J Flux (rate of diffusion per unit area) Determines rate of oral absorption
- D D D Diffusion coefficient of the drug Dependent on molecular weight & viscosity
- K K K Partition coefficient ( K o / w K_{o/w} K o / w ) Ratio of drug solubility in lipid vs water
A A A Surface area of absorption membrane Small intestine microvilli provide ≈ 200 m 2 \approx 200 \text{ m}^2 ≈ 200 m 2
h h h Thickness of membrane barrier Thinner mucosal barriers yield faster absorption
C 1 − C 2 C_1 - C_2 C 1 − C 2 Transmembrane concentration gradient Maintained by rapid systemic blood clearance (sink conditions)
3. Partition Coefficient (log P & log D)
The partition coefficient ( P P P or K o / w K_{o/w} K o / w ) measures a drug's relative lipophilicity by calculating its equilibrium concentration ratio between an organic phase ( n n n -octanol) and an aqueous phase (water):
P = [ C octanol ] [ C water ] un-ionized P = \frac{[C_{\text{octanol}}]}{[C_{\text{water}}]_{\text{un-ionized}}} P = [ C water ] un-ionized [ C octanol ]
Because partition coefficients span multiple orders of magnitude, values are expressed logarithmically as log P \log P lo g P .
log P > 0 \log P > 0 lo g P > 0 : Hydrophobic/lipophilic molecule (prefers octanol).
log P < 0 \log P < 0 lo g P < 0 : Hydrophilic/polar molecule (prefers water).
Optimal Range: Most orally bioavailable drugs possess a log P \log P lo g P between 1 1 1 and 3 3 3 . Drugs with log P > 5 \log P > 5 lo g P > 5 suffer from poor aqueous solubility and erratic dissolution, while drugs with log P < 0 \log P < 0 lo g P < 0 exhibit poor membrane permeability.
Distribution Coefficient ( log D \log D lo g D )
While log P \log P lo g P measures only the un-ionized species, the distribution coefficient ( log D \log D lo g D ) measures the combined equilibrium distribution of both ionized and un-ionized forms at a specific physiological p H p H p H :
log D acid = log P − log 10 ( 1 + 10 ( p H − p K a ) ) \log D_{\text{acid}} = \log P - \log_{10}\left(1 + 10^{(p H - p K_a)}\right) lo g D acid = lo g P − lo g 10 ( 1 + 1 0 ( p H − p K a ) )
log D base = log P − log 10 ( 1 + 10 ( p K a − p H ) ) \log D_{\text{base}} = \log P - \log_{10}\left(1 + 10^{(p K_a - p H)}\right) lo g D base = lo g P − lo g 10 ( 1 + 1 0 ( p K a − p H ) )
log D \log D lo g D provides a far more accurate biological prediction of tissue distribution and membrane permeability in different anatomical compartments.
4. Drug Solubility Enhancement Techniques
Under the Biopharmaceutics Classification System (BCS) , drugs are categorized into four classes based on aqueous solubility and intestinal permeability:
- BCS Class Aqueous Solubility Intestinal Permeability Main Rate-Limiting Step
- Class I High High Gastric emptying rate
- Class II Low High Drug dissolution rate
- Class III High Low Membrane permeation rate
- Class IV Low Low Both dissolution and permeability
Over 40 % 40\% 40% of newly discovered small molecules fall into BCS Class II. To overcome poor aqueous solubility, formulation scientists utilize several established chemical and physical enhancement strategies:
Salt Formation: Converting a weak acid/base into a crystalline salt (e.g., naproxen sodium, diltiazem H C l HCl H Cl ) alters the micro-environmental p H p H p H ( p H max p H_{\text{max}} p H max ) surrounding the dissolving particle, significantly accelerating dissolution rate according to the Noyes-Whitney equation.
Particle Size Reduction (Micronization and Nanonization): Reducing particle size from micrometers to nanometers dramatically increases effective specific surface area ( A A A ), elevating dissolution velocity.
Amorphous Solid Dispersions (ASDs): Dispersing an active drug within a hydrophilic polymeric matrix (such as HPMC or PVP) disrupts the crystal lattice. Because amorphous forms lack lattice energy barriers, they generate supersaturated solutions upon contact with gastrointestinal fluid.
Cyclodextrin Complexation: Cyclic oligosaccharides ( α \alpha α -, β \beta β -, γ \gamma γ -cyclodextrins and hydroxypropyl- β \beta β -cyclodextrin) possess a hydrophobic central cavity and a hydrophilic exterior. Lipophilic drugs entrap within the cavity via non-covalent inclusion complexes, enhancing apparent aqueous solubility.
Self-Emulsifying Drug Delivery Systems (SEDDS/SMEDDS): Isotropic mixtures of oils, surfactants, and co-solvents that spontaneously form fine oil-in-water nano-emulsions ( ≤ 100 nm \le 100 \text{ nm} ≤ 100 nm ) upon mild agitation in GI fluids, presenting the lipophilic drug in pre-dissolved droplets for rapid absorption.